UIC Clinical Research Center
Chicago, Illinois, 60612, United States
NCT Number: NCT02666508
Dental plaque causes caries and periodontal disease and data are sparse about toothpaste and plaque removal. Inflammation, caused by dental plaque, is a risk factor for cardiovascular disease. (CVD) The availability of (Plaque HD (TM), a plaque identifying toothpaste with targetol technology (TM)), afforded the unique opportunity to test whether there were statistically significant and clinically important reductions in plaque and inflammation in a randomized trial of apparently healthy individuals.
Looking for future studies?
Notify Me19 year–45 year
All sexes
Interventional
Not applicable
Chicago, Illinois, 60612, United States
The protocol was approved by the Institutional Review Board of the University of Illinois and the trial was posted on ClinicalTrials.gov. We screened all potentially eligible subjects from the Medical District of the University of Illinois which includes the Colleges of Dentistry, Medicine, Public Health and Pharmacy.
All willing and eligible subjects signed informed consent forms and were instructed to refrain from brushing or flossing teeth, using any oral hygiene aids (such as mouthwash or chewing gum) the evening prior to and the morning of the data collection appointment. All subjects were be asked to complete the following procedures:
The identical procedures were repeated at the 30 day follow up visit.. In addition, the Plaque HD group was instructed to brush in front of a mirror for 1 minute and to concentrate on removing all visible dye. The placebo group was asked to brush their teeth for 1 minute in front of a mirror, using the provided manual toothbrush.
.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The inclusion criteria were as follows:
Exclusion criteria
Plaque identifying toothpaste with targetol
Non-plaque identifying toothpaste without targetol
Time frame: Baseline to 30 - 60 days post baseline
Measure description "percentage" refers to the change in plaque percentage from the baseline to the follow-up visit. The follow-up visit occurred between 30 and 60 days post baseline.
Time frame: Baseline to 30 - 60 days post baseline
Measure description "mg/L" refers to the change in hs-CRP per mg/L from the baseline to the follow-up visit. The follow-up visit occurred between 30 and 60 days post baseline.
Time frame: Baseline to 30-60 days post
Measure description "percentage" refers to the change in plaque percentage from the baseline to the follow-up visit. The follow-up visit occurred between 30 and 60 days post baseline for the Pre-Specified Subgroup (PSS).
Time frame: Baseline to 30-60 days post
Measure description "mg/L" refers to the change in hs-CRP per mg/L from the baseline to the follow-up visit. The follow-up visit occurred between 30 and 60 days post baseline. -PSS analysis
University of Illinois at Chicago
Other
A Randomized Trial of Plaque Identifying Toothpaste on Reduction of Plaque and Inflammation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02718014
Inflammation, Menopause
View Trial DetailsNCT07640399
Bleeding, Gingival Diseases
Mississauga, Ontario, Canada
View Trial DetailsNCT07398846
Gingival Diseases, Gingivitis
Melbourne, Florida, United States
View Trial DetailsNCT06427499
Gingival Diseases, Gingivitis
Ratchathewi, Bangkok, Thailand
View Trial Details